Geode Capital Management LLC Cuts Stock Position in Abbott Laboratories $ABT

Key Points

• Geode Capital Management trimmed its Abbott Laboratories stake by 0.3% in the fourth quarter, selling 134,395 shares and ending with 38.4 million shares valued at about $4.79 billion.
• Several other institutional investors also adjusted their positions, while institutional ownership remains high at 75.18% of Abbott’s stock.
• Analysts have recently cut price targets, but the stock still carries a Moderate Buy consensus; Abbott also reported quarterly results that beat estimates and raised FY2026 guidance.

Geode Capital Management LLC decreased its holdings in Abbott Laboratories (NYSE:ABT - Free Report) by 0.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 38,407,499 shares of the healthcare product maker's stock after selling 134,395 shares during the quarter. Geode Capital Management LLC owned 2.21% of Abbott Laboratories worth $4,790,674,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in ABT. Fidelis Capital Partners LLC lifted its holdings in Abbott Laboratories by 7.5% during the 4th quarter. Fidelis Capital Partners LLC now owns 28,522 shares of the healthcare product maker's stock worth $3,574,000 after buying an additional 1,992 shares in the last quarter. King Luther Capital Management Corp lifted its holdings in Abbott Laboratories by 2.0% during the 4th quarter. King Luther Capital Management Corp now owns 1,464,440 shares of the healthcare product maker's stock worth $183,480,000 after buying an additional 28,981 shares in the last quarter. Expressive Wealth LLC acquired a new stake in Abbott Laboratories during the 4th quarter worth approximately $428,000. GHE LLC lifted its holdings in Abbott Laboratories by 4.7% during the 4th quarter. GHE LLC now owns 13,432 shares of the healthcare product maker's stock worth $1,683,000 after buying an additional 609 shares in the last quarter. Finally, Syverson Strege & Co grew its position in shares of Abbott Laboratories by 22.0% during the fourth quarter. Syverson Strege & Co now owns 14,534 shares of the healthcare product maker's stock worth $1,821,000 after buying an additional 2,617 shares in the last quarter. Institutional investors and hedge funds own 75.18% of the company's stock.

Analyst Ratings Changes

Several brokerages recently weighed in on ABT. Royal Bank Of Canada reduced their target price on shares of Abbott Laboratories from $135.00 to $130.00 and set an "outperform" rating on the stock in a report on Friday, April 17th. Barclays dropped their price objective on shares of Abbott Laboratories from $144.00 to $143.00 and set an "overweight" rating on the stock in a research report on Monday, April 20th. Wells Fargo & Company reduced their price objective on shares of Abbott Laboratories from $122.00 to $109.00 and set an "overweight" rating on the stock in a report on Friday, April 17th. Sanford C. Bernstein lowered their target price on shares of Abbott Laboratories from $125.00 to $110.00 and set an "outperform" rating for the company in a research note on Friday, April 17th. Finally, Stifel Nicolaus dropped their target price on Abbott Laboratories from $145.00 to $120.00 and set a "buy" rating on the stock in a report on Friday, April 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $119.09.

Insider Buying and Selling

In related news, Director Daniel J. Starks purchased 10,000 shares of the company's stock in a transaction on Monday, April 27th. The shares were bought at an average cost of $92.65 per share, for a total transaction of $926,500.00. Following the completion of the purchase, the director directly owned 6,751,103 shares of the company's stock, valued at approximately $625,489,692.95. This trade represents a 0.15% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Eric Shroff sold 709 shares of the stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $81,946.22. Following the completion of the transaction, the senior vice president owned 39,164 shares in the company, valued at $4,526,575.12. This represents a 1.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 3,055 shares of company stock valued at $353,097 over the last three months. 0.46% of the stock is currently owned by insiders.

Abbott Laboratories News Roundup

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott won FDA clearance and EU CE Mark approval for Ultreon 3.0, an AI-powered coronary imaging tool that helps guide artery stent placement, which could support future med-tech growth. Abbott (ABT) Wins FDA and EU Approval for an AI-Powered Tool That Guides Artery Stent Placement
• Positive Sentiment: The company secured CE Mark for Libre Duo, the world’s first dual glucose-ketone sensing technology, expanding its diabetes care lineup and potentially strengthening its CGM franchise. Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes
• Positive Sentiment: Updated American Cancer Society guidelines reaffirmed Cologuard and Cologuard Plus as preferred noninvasive colorectal cancer screening options, reinforcing Abbott’s position in cancer diagnostics. ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening
• Neutral Sentiment: Abbott’s diagnostics unit showed mixed first-quarter trends, with core lab growth offset by weakness in China and softer respiratory testing demand, suggesting an uneven outlook in that segment. How Abbott's Diagnostics Unit Is Shaping Up Through the Rest of 2026
• Negative Sentiment: Goldman Sachs lowered its price target on Abbott to $113 from $121, even while maintaining a buy rating, adding some caution around near-term upside. Goldman Sachs adjusts price target on Abbott Laboratories to 113 from 121, maintains buy rating
• Negative Sentiment: Separately, commentary highlighted headwinds in Abbott’s nutrition business, which may be weighing on investor sentiment. Abbott Laboratories (ABT) Slid on Headwinds in Nutrition Business

Abbott Laboratories Stock Performance

Shares of Abbott Laboratories stock opened at $85.70 on Thursday. The firm has a market capitalization of $149.27 billion, a P/E ratio of 24.00, a P/E/G ratio of 1.45 and a beta of 0.65. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $139.06. The company has a quick ratio of 1.01, a current ratio of 1.39 and a debt-to-equity ratio of 0.56. The firm's 50 day moving average is $95.41 and its two-hundred day moving average is $111.15.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, beating the consensus estimate of $1.14 by $0.01. The company had revenue of $11.16 billion for the quarter, compared to analyst estimates of $10.99 billion. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The firm's revenue was up 7.8% on a year-over-year basis. During the same period in the prior year, the firm posted $1.09 earnings per share. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Research analysts forecast that Abbott Laboratories will post 5.48 EPS for the current fiscal year.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.